COVID-19: BNT-162: An Exploratory Phase 1, Randomized, Observer-Blind, Active-Controlled Dose Escalation Trial Evaluating the Safety, Tolerability and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Health

Grants and Contracts Details

StatusActive
Effective start/end date1/6/231/11/25

Funding

  • BioNTech SE: $73,220.00